Canadian acquisition giant Valeant Pharmaceuticals announced it will buy eye surgery product maker Synergetics USA for as much as $192 million.
Missouri-based Synergetics manufactures devices primarily for use in vitreoretinal surgery and neurosurgical applications. This acquisition will strengthen Bausch+Lomb business, which Valeant bought for $8.7 billion in 2013.
Earlier this week, Valeant announced that it will collaborate with AstraZeneca on psoriasis treatment brodalumab, after Amgen dropped out of the deal in May.
Read the SF Gate release